Athira Pharma IncChange company Symbol lookupSelect an option...ATHA Athira Pharma IncCEVIY China Everbright LtdPATK Patrick Industries IncTGHI Touchpoint Group Holdings IncPIAI^ Prime Impact Acquisition ICGEN Compugen LtdFPAY FlexShopper IncIOACW Innovative International Acquisition Equity Warrants Exp 26th Oct 2026 *W EXP 10/26/2026FUSN Fusion Pharmaceuticals IncCOUR Coursera IncGo
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company's lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, blood brain barrier (BBB)-penetrating, small molecule HGF/MET positive modulator. The primary target indication is Alzheimers disease. The ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer's disease (AD). It also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019/ATH-1020 compounds, which are being advanced to address neuropsychiatric indications. ATH technology is designed to promote HGF/MET activity for a variety of clinical applications.
|
|
|
|
| |
Company Profile
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company's lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, blood brain barrier (BBB)-penetrating, small molecule HGF/MET positive modulator. The primary target indication is Alzheimers disease. The ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer's disease (AD). It also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019/ATH-1020 compounds, which are being advanced to address neuropsychiatric indications. ATH technology is designed to promote HGF/MET activity for a variety of clinical applications.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- --
- Price/Book (MRQ)
- 0.48x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- Kelly A. Romano
- Mark James LittonPres.
- Glenna MilesonCFO
- Rachel LeningtonCOO
- Kevin ChurchExec.VP
Address
- 18706 North Creek Parkway
- Bothell, WA 98011
- Phone: (425) 620-8501
- Fax: (302) 636-5454
- https://www.athira.com/
Insider Trading
During the most recent quarter, 1M shares were bought, and 20K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.